Showing 1 - 20 results of 90,419 for search '(((( 6 0 decrease ) OR ( _ stem decrease ))) OR ( 50 ((nn decrease) OR (_ decrease)) ))*', query time: 0.78s Refine Results
  1. 1

    GSK343 decreased tumor stemness. by Laura V. Bownes (10276762)

    Published 2021
    “…(C) COA6 cells were treated with GSK343 (0, 5 μM) for 72 hours. qPCR demonstrated a significant decrease in mRNA abundance of known stemness markers Oct4, Nanog, and Sox2 following GSK343 treatment compared to untreated cells. …”
  2. 2
  3. 3

    Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s. by Djaloul Karboua (16510091)

    Published 2023
    “…<p>Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s.…”
  4. 4
  5. 5
  6. 6

    <i>Kdm6a</i> conditional KO mice have decreased repopulating potential in serial competitive transplantation assays. by Ling Tian (107492)

    Published 2021
    “…The respective curves showed a decreased repopulation potential for all three cohorts of <i>Kdm6a</i> conditional KO mice, which was most pronounced in KO-F mice. …”
  7. 7
  8. 8

    Decreased ISCs and increased goblet cells after intestinal specific loss of MLL1. by Neha Goveas (11790822)

    Published 2021
    “…Mean ± s.d. is shown (p = 0.007, Student’s <i>t</i>-test). (C) Decrease in ISC markers, OLFM4 and SOX9 in <i>Mll1</i><sup><i>FC/FC; Vil-Cre-ERT2/+</i></sup> intestinal sections. …”
  9. 9

    Naloxone reverses morphine increased-caspase-3 activity, neuronal differentiation and decreased NPC expression. by Dafna Willner (605895)

    Published 2014
    “…Morphine 13 =  Morphine 13 µM; Naloxone 50 =  Naloxone 50 µM (<b>6A, 6B</b>).</p>…”
  10. 10
  11. 11
  12. 12

    MBCD decreased stemness in MDA-MB-231. by Ankit Sharma (578833)

    Published 2019
    “…(<b>E</b>) RT-PCR analysis was performed using total RNA and gene specific primers. Decreased levels of stemness markers CD44 and BMI1 were found in MBCD treated cells. …”
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  20. 20